Di­a­betes and weight loss drug ad­ver­tis­ing tops $1B on strength of GLP-1 brand spend­ing

The new class of GLP-1 drug brands is dri­ving di­a­betes and weight loss pre­scrip­tion drug ad­ver­tis­ing spend­ing, push­ing the com­bined cat­e­go­ry to more than $1 bil­lion last year, and with no end in sight for 2024.

Last year’s boost was a more than 50% in­crease over di­a­betes and weight loss drug me­dia spend­ing the pre­vi­ous year, ac­cord­ing to ad in­tel­li­gence com­pa­ny Me­di­aRadar. Four GLP-1 brands — Moun­jaro, Ozem­pic, Ry­bel­sus and We­govy  — ac­count­ed for more than $809 mil­lion of the more than $1 bil­lion spend, ac­cord­ing to Me­di­aRadar’s da­ta. The re­main­ing spend­ing came from oth­er pre­scrip­tion di­a­betes brands.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER